Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs
Prelude Therapeutics shares traded higher in premarket action Thursday, after the cancer-drug maker showed up at an investor event in New York on Wednesday. The move brought the stock back into focus for traders. Prelude last traded at $3.66 for a market cap near $302 million. The SPDR S&P Biotech ETF was up 1.6% in its latest trade. The iShares Nasdaq Biotechnology ETF gained 2.0%.